2009 Top 20 Pharmaceutical Companies Report

They don’t call them “Big Pharma” for nothing! Several of the industry’s biggest players decided to get bigger via M&A this year, which means next year’s ranks are going to feature at least three new players, once Wyeth and Schering-Plough are swallowed up and Roche moves over to the Top Biopharma ranks. And I do mean top!

It’s a good thing my “Pharm System” has a whole crop of new companies to move into the ranks — you’re on deck, Gilead! — but how will all these mergers and consolidations affect contract service providers? Columnist Michael Martorelli has some thoughts on the subject in this issue, but pharma companies remain quiet about how they’ll reconcile their internal mega-networks with their outsourcing strategies. So stay tuned . . .

—Gil Y. Roth, Editor

 

Top 20 Pharmaceutical Companies
01	Pfizer	$44,174
02	Sanofi-Aventis	$40,562
03	GlaxoSmithKline	$37,810
04	Novartis	$35,647
05	AstraZeneca	$30,677
06	Merck	$25,901
07	Johnson & Johnson	$24,567
08	Roche	$23,624
09	Eli Lilly & Co.	$19,285
10	Bristol-Myers Squibb	$17,715
11	Wyeth	$17,391
12	Schering-Plough	$16,534
13	Abbott Laboratories	$16,013
14	Takeda	$13,841
15	Bayer Schering	$13,803
16	Boehringer Ingelheim	$13,405
17	Teva*	10,482
18	Astellas*	$9,646
19	Daiichi-Sankyo*	$7,900
20	Eisai*	$7,612

Based on 2008 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company’s page.

* PDF profiles only available for companies 17-20

 

Contributors

Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Bayer-Schering, by Kristin Brooks.

The Lowe Down capsules written by Derek Lowe

All pipeline information compiled by Kristin Brooks

Sales information compiled by Gil Roth

Looking for the Top 10 Biopharma companies report? Look no further!